TY - JOUR
T1 - Strategic Outlook toward 2030
T2 - Japan's research for allergy and immunology – Secondary publication
AU - Adachi, Takeya
AU - Kainuma, Keigo
AU - Asano, Koichiro
AU - Amagai, Masayuki
AU - Arai, Hiroyuki
AU - Ishii, Ken J.
AU - Ito, Komei
AU - Uchio, Eiichi
AU - Ebisawa, Motohiro
AU - Okano, Mitsuhiro
AU - Kabashima, Kenji
AU - Kondo, Kenji
AU - Konno, Satoshi
AU - Saeki, Hidehisa
AU - Sonobe, Mariko
AU - Nagao, Mizuho
AU - Hizawa, Nobuyuki
AU - Fukushima, Atsuki
AU - Fujieda, Shigeharu
AU - Matsumoto, Kenji
AU - Morita, Hideaki
AU - Yamamoto, Kazuhiko
AU - Yoshimoto, Akemi
AU - Tamari, Mayumi
N1 - Publisher Copyright:
© 2020 Japanese Society of Allergology
PY - 2020/10
Y1 - 2020/10
N2 - Strategic Outlook toward 2030: Japan's Research for Allergy and Immunology (Strategy 2030) is the national research strategy based on Japan's Basic Law on Measures Against Allergic Diseases, a first of its kind worldwide. This strategy was established by a multi-disciplinary committee consisting of administrators of the Ministry of Health, Labour and Welfare of Japan, young and senior experts from various research societies and associations, and representatives of patient and public groups. Whereas the issues of transition, integration, and international collaboration have yet to be solved in this research realm in Japan, identification of unmet needs, digitization of information and transparent procedures, and strategic planning for complex problems (a process dubbed MIERUKA by the Toyota Way) are crucial to share and tackle the same vision and goals. The committee developed three specific actions focusing on preemptive treatment, interdisciplinarity and internationality, and life stage. The real success of Strategy 2030 is made by the spontaneous contributions of doctors, dentists, veterinarians, and other medical professionals; basic and clinical research scientists, research supporters, and pharmaceutical/medical device companies; manufacturers of food, healthcare, and home appliances; and patients, their families, and the public. The hope is to establish a stable society in which people can live long, healthy lives, as free as possible from allergic and immunological diseases, at each individual life stage. This article is based on a Japanese review first reported in Arerugi, introduces the developmental process and details of Strategy 2030.
AB - Strategic Outlook toward 2030: Japan's Research for Allergy and Immunology (Strategy 2030) is the national research strategy based on Japan's Basic Law on Measures Against Allergic Diseases, a first of its kind worldwide. This strategy was established by a multi-disciplinary committee consisting of administrators of the Ministry of Health, Labour and Welfare of Japan, young and senior experts from various research societies and associations, and representatives of patient and public groups. Whereas the issues of transition, integration, and international collaboration have yet to be solved in this research realm in Japan, identification of unmet needs, digitization of information and transparent procedures, and strategic planning for complex problems (a process dubbed MIERUKA by the Toyota Way) are crucial to share and tackle the same vision and goals. The committee developed three specific actions focusing on preemptive treatment, interdisciplinarity and internationality, and life stage. The real success of Strategy 2030 is made by the spontaneous contributions of doctors, dentists, veterinarians, and other medical professionals; basic and clinical research scientists, research supporters, and pharmaceutical/medical device companies; manufacturers of food, healthcare, and home appliances; and patients, their families, and the public. The hope is to establish a stable society in which people can live long, healthy lives, as free as possible from allergic and immunological diseases, at each individual life stage. This article is based on a Japanese review first reported in Arerugi, introduces the developmental process and details of Strategy 2030.
KW - Allergy
KW - Immunology
KW - Japan
KW - MHLW
KW - Strategy
UR - http://www.scopus.com/inward/record.url?scp=85087022864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087022864&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2020.04.006
DO - 10.1016/j.alit.2020.04.006
M3 - Review article
C2 - 32600925
AN - SCOPUS:85087022864
SN - 1323-8930
VL - 69
SP - 561
EP - 570
JO - Allergology International
JF - Allergology International
IS - 4
ER -